Skip to content

Released Feb 3, 2023, before the open

10-Q filed Feb 3, 2023, 34 days after period end · 0001764013-23-000022

Q3 2023 · 10-Q
Revenue—
Net Income-$63.23MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.49N/M vs Q3 2022N/M vs Q2 2023
Operating Cash Flowderived-$46,395,000N/M
Free Cash Flowderived-$46,493,000N/M

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2018
Net Income-$63.23M-$41.39M-$8.85M
EPS Diluted-$0.49-$0.36-$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR